Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial - Gastroenterology
ABX464's Clinical Benefits for Inflammatory Diseases Revealed in Review
Targeting the Long Non-Coding RNA LINC00599-205 splicing by novel candidate drug ABX464 to produce the anti-inflammatory microRNA miR-124 | bioRxiv
Mechanism of action of anti-HIV drug, ABX464, published
Abivax | LinkedIn
Abivax: A Biotech With Blockbuster Potential (OTCMKTS:AAVXF) | Seeking Alpha
Global Roundup: Abivax Eyes Phase III Following Positive UC Data | BioSpace
HIV pipeline report 2019 | HTB | HIV i-Base
Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases: Trends in Molecular Medicine
HIV pipeline 2017: full version | HTB | HIV i-Base
Abivax receives Phase IIb trial authorisation from Canada for ABX464
Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases - ScienceDirect
ABIVAX: 2016 Full-Year Results and Progress Report | Business Wire
Abivax's ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for success - Pharma Technology Focus | Issue 98 | September 2020
Abivax reports excellent efficacy and safety of ABX464 in Phase IIb
Abivax First-Half 2018 Financial Results and Operations Update | Abivax
Abivax (@Abivax_) / Twitter
Abivax 2018 Financial Results and Operations Update | Business Wire
Abivax to evaluate anti-inflammatory effects of ABX464 in large-scale COVID-19 trial – Truffle
Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases - ScienceDirect
Abivax's ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for success - Pharma Technology Focus | Issue 98 | September 2020
Tweets with replies by Abivax (@Abivax_) / Twitter
Targeting the Long Non-Coding RNA LINC00599-205 Splicing by Novel Candidate Drug ABX464 To Produce the Anti-Inflammatory MicroRNA MiR-124
Frontiers | Microglial Cells: The Main HIV-1 Reservoir in the Brain | Cellular and Infection Microbiology
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing. - Abstract - Europe PMC
Abivax: Most Ideal Big Pharma M&A Target In 2022 (AAVXF) | Seeking Alpha
